GlassScriptPhysician profile
Andrew Stephen Goldberg
NPI 1184623936
$6,073.63
in general payments reported to CMS, 2019-2025
22 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,268 · 2020: $1,457 · 2021: $1,856 · 2023: $251 · 2024: $43.08 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $413 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.04 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,240.19 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Astrazeneca Pharmaceuticals LP | $1,011.03 | 2019-2023 | Fasenra, Breztri, Tezspire |
| Grifols USA, LLC | $675.23 | 2019-2023 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $605.97 | 2019-2023 | Trelegy Ellipta |
| Genzyme Corporation | $329.89 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $304.48 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $237.12 | 2020-2025 | Uptravi, Opsumit |
| Genentech USA, INC. | $232.43 | 2019-2021 | |
| Advanced Respiratory, INC | $214.33 | 2019-2021 | |
| Optinose US, INC. | $197.52 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $181.85 | 2020-2023 | Dupixent |
| Gilead Sciences, INC. | $169.96 | 2019-2021 | |
| Electromed, INC. | $150.34 | 2019-2021 | |
| Insmed, INC. | $133.92 | 2021-2025 | Brinsupri |
| Sanofi-Aventis U.S. LLC | $108.85 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $102.09 | 2019-2020 | |
| Inspire Medical Systems, INC. | $66.87 | 2023-2024 | Inspire |
| Verona Pharma, INC. | $39.93 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $30.97 | 2021 | |
| Merck Sharp & Dohme LLC | $22.81 | 2023 | |
| Fisher & Paykel Healthcare INC | $12.85 | 2021 | |
| United Therapeutics Corporation | $5.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.